Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- Bcl2 Escherichia hydro phobic antiapoptotic
- Product Overview:
Bcl-2 is an anti-apoptotic protein and the founding member of the Bcl-2 family of proteins.{16714,65031} Bcl-2 is composed of a C-terminal helix that acts as a membrane anchor and four highly conserved Bcl-2 homology (BH) domains.{16714} The BH1, BH2, and BH3 domains form a hydrophobic cleft that mediates protein-protein interactions with the pro-apoptotic proteins Bax and Bak, resulting in their inhibition, whereas the BH4 domain regulates intracellular calcium levels by interacting with the inositol-1,4,5-triphosphate receptor (IP3R) and ryanodine receptors (RyRs).{65030,16714,55181} Bcl-2 is highly expressed during embryogenesis and neuron and lymphocyte development and is primarily localized to the mitochondrial outer membrane.{55182} It inhibits the intrinsic apoptotic pathway by inhibiting Bax- or Bak-induced pore formation in the outer mitochondrial membrane, maintaining the mitochondrial membrane potential, and preventing the release of cytochrome c into the cytosol and the induction of apoptosis.{65031,65030} Bcl-2 has oncogenic function, promoting tumor progression and angiogenesis, as well as metastasis.{55181} The Bcl2 t(14;18)(q32;q21) translocation results in Bcl-2 overexpression and is a hallmark of follicular lymphoma.{65032} Bcl-2 is also overexpressed in several other cancers, including chronic lymphocytic leukemia (CLL), diffuse large B cell lymphoma (DLBCL), and prostate cancer.{65030} Cayman’s Bcl-2 (human, recombinant) protein can be used for binding assays. This protein consists of 221 amino acids and has a calculated molecular weight of 24.7 kDa.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.